– USA, MA – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) today announced the election of Dr. Arturo Molina (M.D., M.S., F.A.C.P.) to its board of directors and R&D committee.
“I am excited to welcome Arturo at this pivotal stage of growth for Forma,. Arturo’s exceptional clinical and administrative acumen in the fields of hematology and oncology will inform Forma’s work as it continues advancing treatments to meet the needs of these important patient populations,” ” said Board Chair, Peter Wirth.
Frank Lee, CEO added, “We are thrilled Arturo is joining us at Forma. His global clinical, drug development and launch experience will be vital to Forma as we continue to develop therapies to transform patients’ lives around the world. Arturo’s operational and strategic experience in pioneering new solutions will help us to deliver on our mission in very concrete ways as we work to ensure our therapies are successful in the clinic and ultimately reach patients in need.”
About Dr. Arturo Molina
Dr. Molina is an internationally acclaimed clinician, hematology and oncology researcher, practicing physician, and pioneer for change in healthcare inequities. He has over 25 years of experience in biopharma, hematology, and oncology and currently serves as CMO at Sutro Biopharma, where he is responsible for the clinical development of oncology and hematology therapeutics. Before Sutro, Dr. Molina served as VP of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center and CMO and VP of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, CMO at Cougar Biotechnology which was acquired by Johnson and Johnson and Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc.
Additionally, Dr. Molina is a member of the American Society of Hematology’s Committee on Promoting Diversity and the National Advisory Committee of the Amos Medical Faculty Development Program, a Robert Wood Johnson Foundation program focused on increasing the number of medical, dental, and nursing faculty from historically disadvantaged backgrounds. Dr. Molina is also an adjunct clinical associate professor at the Stanford School of Medicine, Oncology Division.
“I am honored to join the board and R&D Committee of Forma, whose unequivocal patient-focused and culturally aware approach to challenging diseases aligns with my work. I’m eager to share my clinical drug development and research expertise to advance Forma’s exciting pipeline and patient-focused mission,” said Dr. Arturo Molina.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise, and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet needs. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefits.
For more information: https://www.formatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
